/f/125658/5000x1496/8aa45c8224/eacvi-acronym-text-rgb.png)
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Dr. Rigolli is a Cardiologist, Physician-Scientist (MD, DPhil), Director of Cardiovascular Global Drug Development with expertise in Cardiovascular Imaging, Cardiomyopathies, Heart Failure and Valvular Heart Disease. She trained in Cardiovascular Medicine at the University of Verona, Italy, and at the University of Oxford, United Kingdom.
Dr. Rigolli obtained highest expert qualifications in CMR and CT after multi-modality imaging fellowships in Oxford, UK and Auckland, NZ. Her doctoral studies were awarded a DPhil (PhD) from the University of Oxford in 2019 before moving to the US to work on Rare Diseases and Imaging at the University of California, San Diego. Her academic research examined the role of imaging in assessing clinical outcomes and treatment targets.
Dr. Rigolli is currently developing drugs in cardiomyopathies (HCM) and Heart Failure. She is passionate about clinical trials, publishes in high-impact journals, and has won multiple young investigator awards.
Right ventricular dysfunction is associated with late mortality in severe aortic stenosis: results from a multi-centre outcome study in patients undergoing aortic valve replacement
Event: ESC Congress 2019
Topic: Epidemiology, Prognosis, Outcome
Session: Imaging parameters in valvular heart disease
ESC 365 is supported by
